

Ref. No: 1240
Date: 03/10/24
Subject: Biologic medicines in gastroenterology

REQUEST

How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Etrasimod
- Filgotinib
- Golimumab
- Infliximab - Remicade
- Infliximab Biosimilar
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab
- Ustekinumab Biosimilar
- Vedolizumab

RESPONSE

- Adalimumab – Humira - 5
- Adalimumab Biosimilar- 178
- Etrasimod - 0
- Filgotinib - 8
- Golimumab - 2
- Infliximab – Remicade - 54
- Infliximab Biosimilar – 212
- Mirikizumab - 2

- **Ozanimod - 1**
- **Risankizumab - 9**
- **Tofacitinib - 16**
- **Upadacitinib - 3**
- **Ustekinumab - 126**
- **Ustekinumab Biosimilar - 2**
- **Vedolizumab - 89**